Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | F7 | P08709 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226490 | 1.00 | PTGS2 (0.46) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL441945 | 1.00 | PTGS2 (0.46) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL13491259 | 0.95 | ADORA3 (0.50) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL3216691 | 0.89 | ADORA3 (0.43) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL27757362 | 0.89 | ADORA3 (0.43) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL3216696 | 0.89 | ADORA3 (0.43) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL3265006 | 0.86 | ADORA3 (0.46) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL3265008 | 0.86 | ADORA3 (0.46) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL444167 | 0.86 | ADORA3 (0.46) | PTGS2ADORA3NR1I2PGRPDE4D | |
| SCHEMBL13491256 | 0.85 | ADORA3 (0.47) | PTGS2ADORA3NR1I2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399516-B2 | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2013-03-19 | — | — | US | disclosed |
| US-8399516-B2 | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2013-03-19 | — | — | US | disclosed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PPARG, PPARA, FFAR3 | PTGS2 228/4885ADORA3 201/4885NR1I2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.